SYN The new price target of $6 by Maxim is very nice and a long way off from here. On Schwab they have a nice write up of reasoning, I will try to find it elsewhere. Finviz has an article Short story -
8:58 am Synthetic Biologics target raised to $6 at Maxim Group following meetings with mgmt
Maxim Group raises its SYN tgt to $6 from $3. Firm concludes that there are now multiple events ahead, including top-line data for Trimesta (oral estriol) in relapsing/remitting multiple sclerosis in April. In addition, SYN-004 (a second-generation product) should progress to the clinic (for the start of a phase 1b/2 trial) for the prevention of C-difficile infection. SYN-005 (mAb) for pertussis (whooping cough) is another catalyst that has shown compelling animal data (whooping cough is an unmet medical need), as well as the development of SYN-010 for C-IBS and related GI disorders and SYN-001 for life-threatening Acinetobacter (gram negative bacterium) infections.
News 
Market Data 
Discover 
AI
